Diabetes Watch Time: 24 mins

touchEXPERT OPINIONS How can the selection of patients with type 1 diabetes suitable for adjunctive treatment with SGLT inhibitors be optimized?

Watch two experts discuss the use of sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin in patients with type 1 diabetes (T1D).

Manon Khazrai, Dietitian and Diabetes Counsellor, considers why there is a need for adjunctive therapy and why SGLT inhibitors are a suitable option. Debbie Hicks, Nurse Consultant – Diabetes, provides insight into patient selection and mitigating the risk of diabetic ketoacidosis.

Now Playing:
Up Next:
 
Dr Manon Khazrai
Bio-Medico University, Rome, Italy
What is the rationale for using SGLT inhibitors as an adjunct to insulin therapy in patients with type 1 diabetes?

Manon Khazrai, Dietitian and Counsellor, Campus Bio-Medico University, Rome, Italy, discusses the need for adjunctive therapy in some patients with type 1 diabetes (T1D) and why sodium-glucose co-transporter (SGLT) inhibitors may be a suitable option.

1/2 Next Interview
Leave Feedback
Interview Questions
  • What is the impact of poor glycaemic control in people with T1D?
  • Why do some people with T1D not achieve good glycaemic control?
  • What is the ideal profile for an adjunctive therapy to insulin in people with T1D?
  • What are SGLT inhibitors and how do they improve glycaemic control?
  • Why do people suitable for consideration for adjunctive therapy with an SGLT inhibitor need to have a BMI >27 kg/m2?
  • What impact do the SGLT inhibitors have on other microvascular and macrovascular diabetic complications?
About Dr Manon Khazrai

Dr Khazrai is a lecturer of Nutrition and Food Sciences at Campus Bio-Medico University, Rome, Italy. She is a dietitian, diabetes educator and person-centred counsellor and performs her clinical work at the outpatient clinic of the University Hospital.

Since 2001, Dr Khazrai has conducted research with the Endocrinology and Diabetes Clinic of the Campus Bio-Medico University and provides counselling for family members of adolescents with T1D. She has also been involved in the TRIGR (Trial to Reduce IDDM in the Genetically at Risk) trial within Italy.

Disclosures: None

 
Mrs Debbie Hicks
Founding Member and Co-Chair of TREND-UK
How can we select patients for adjunctive therapy with SGLT inhibitors and mitigate against adverse events?

Debbie Hicks, Nurse Consultant, Diabetes, and founding member and Co-Chair of TREND-UK, discusses how to select patients with type 1 diabetes (T1D) suitable for adjunctive treatment with sodium-glucose co-transporter (SGLT) inhibitors and the mitigation strategies for the known potential side effect diabetic ketoacidosis (DKA).

2/2 Leave Feedback
Leave Feedback
Interview Questions
  • Which patients with T1D should be considered for adjunctive therapy with an SGLT inhibitor?
  • What is DKA?
  • Why are people with T1D prone to DKA?
  • What is the clinical trial evidence for the safety of SGLT inhibitors in people with T1D?
  • How can we mitigate the risk of DKA?
About Mrs Debbie Hicks

Mrs Hicks is a Nurse Consultant, Diabetes, for Medicus Health Partners, Enfield, UK. She is also a founding member and Co-Chair of TREND (Training, Research and Education for Nursing in Diabetes)-UK and Chair of Injection Technique Matters.

Mrs Hicks has worked in diabetes nursing since 1990 and has published over 140 papers in that time. She has been a member of the editorial board of the Journal of Diabetes Nursing since it was first published, and she was the editor-in-chief for over 10 years. She is currently a member of the editorial board of The Diabetes Times.

Disclosures: Debbie Hicks has worked in an advisory capacity and presented for: Boehringer Ingelheim, B Braun, GlucoRx, Lilly, MSD, Mylan, Napp, Novo Nordisk, Owen Mumford, Sanofi andTakeda. She has also accepted sponsorship to attend educational meetings from Lilly. MSD and Novo Nordisk. She is Director of TREND-UK (Diabetes) Ltd and CreativeDiabetes Ltd.

Leave Feedback
Overview & Learning Objectives
Overview

Watch two experts discuss the use of sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin in patients with type 1 diabetes (T1D).

Manon Khazrai, Dietitian and Diabetes Counsellor, considers why there is a need for adjunctive therapy and why SGLT inhibitors are a suitable option. Debbie Hicks, Nurse Consultant – Diabetes, provides insight into patient selection and mitigating the risk of diabetic ketoacidosis.

This activity is intended for specialist diabetes nurses, diabetes educators, dietitians and related specialists involved in the treatment of patients with T1D.

Learning Objectives

After watching this touchEXPERT OPINIONS, you should be able to:

  • Describe the rationale for using sodium-glucose co-transporter (SGLT) inhibitors as an adjunct to insulin therapy in patients with type 1 diabetes (T1D)
  • Recognize patients with T1D who are suitable for treatment with an SGLT inhibitor as an adjunct to insulin therapy
  • Describe the risk factors for and key signs and symptoms of diabetic ketoacidosis (DKA), especially euglycemic DKA

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchEXPERT OPINIONS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar